Table 4.
Antiviral activities in single-round and multiple-round infection assays
| Drug |
NL4-3 EC
50
(μM) |
SR/MR ratio | |
|---|---|---|---|
| Single-round | Multiple-round | ||
| EFV |
0.0012 ± 0.0004 |
0.0013 ± 0.0002 |
0.9 |
| RAL |
0.0025 ± 0.0003 |
0.0024 ± 0.0006 |
1 |
| EVG |
0.00042 ± 0.00005 |
0.00086 ± 0.0004 |
0.5 |
| NVP |
0.041 ± 0.008 |
0.086 ± 0.012 |
0.5 |
| AZT |
0.0025 ± 0.0003 |
0.0024 ± 0.0006 |
0.6 |
| IDV |
Inactive |
0.036 |
NA |
| SQV |
Inactive |
0.013 |
NA |
| Mut029 |
30 ± 4 |
3.8 ± 1.6 |
8 |
| Mut047 |
37 ± 2 |
16 ± 7 |
2.3 |
| Mut049 |
41 ± 2 |
2.0 ± 0.1 |
21 |
| Mut062 |
30% @50 |
3.3 ± 1.5 |
>25 |
| Mut075 |
23% @50 |
3.4 ± 1.0 |
>25 |
| Mut101 | 9.0 ± 1.5 | 0.49 ± 0.04 | 18 |
EC50 for the ARV activity of Mut101 compound series (tested in SR and MR assays) and the SR/MR ratio compared to the indicated drugs. Data represent the mean of six independent experiments.